Explore the words cloud of the Ebola_Tx project. It provides you a very rough idea of what is the project "Ebola_Tx" about.
The following table provides information about the project.
Coordinator |
PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE
Organization address contact info |
Coordinator Country | Belgium [BE] |
Project website | http://www.ebolatx.eu/ |
Total cost | 3˙035˙428 € |
EC max contribution | 2˙892˙171 € (95%) |
Programme |
1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being) |
Code Call | H2020-Adhoc-2014-20 |
Funding Scheme | RIA |
Starting year | 2014 |
Duration (year-month-day) | from 2014-11-01 to 2016-10-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE | BE (ANTWERPEN) | coordinator | 1˙803˙778.00 |
2 | ETABLISSEMENT FRANCAIS DU SANG | FR (LA PLAINE SAINT DENIS) | participant | 385˙775.00 |
3 | INSTITUT PASTEUR | FR (PARIS CEDEX 15) | participant | 242˙910.00 |
4 | UNIVERSITE D'AIX MARSEILLE | FR (Marseille) | participant | 218˙151.00 |
5 | THE UNIVERSITY OF LIVERPOOL | UK (LIVERPOOL) | participant | 85˙180.00 |
6 | LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER | UK (LONDON) | participant | 60˙110.00 |
7 | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD | UK (OXFORD) | participant | 49˙100.00 |
8 | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | FR (PARIS) | participant | 47˙166.00 |
The objective of this proposal is to urgently determine the efficacy, safety and feasibility of convalescent whole blood (CWB) and convalescent plasma (CP) therapy, as a treatment for patients with Ebola Viral Disease (EVD) to reduce the case fatality rate in the present EVD epidemic in West Africa.
The trial will take place in three consecutive phases; i) initial phase to initiate harmonized standard supportive care (SC), ii) evaluation of CWB iii) evaluation of CP. Supportive care (SC) including intravenous hydration and shock management will be standardised and made available to all patients. Day 14 mortality will be used to determine primary outcome. Survival for patients treated with CWB SC or CP SC will be compared to SC alone using a non-randomised open-label design. Based on available figures, a 20% decrease in the case fatality rate will be considered proof of clinical efficacy. Internationally agreed stands of ethics and human rights will be applied for the duration of the trial. Written consent will be requested from patients and/or guardians of patients. Every consideration will be given to the safely of health-care workers involved in the trial, including their consent to be involved and adequate training and psycho-emotional support. Given the study context, community communication will be prioritized. We propose a unique partnership of academics, clinical trial units, non-governmental organizations, international research networks, international and local actors to conduct a clinical trial according to the highest standards attainable in the current context. If found to be effective, this intervention can be scaled-up relatively rapidly as the trial will provide the information required to mobilize local partners, with major public health implications.
Pre-trial anthropological assessments completed | Documents, reports | 2019-07-24 14:21:23 |
Analysis of survival rate of CWB on cohort of 100 patients | Demonstrators, pilots, prototypes | 2019-07-24 14:21:23 |
Comprehensive community mobilization strategy evaluated | Documents, reports | 2019-07-24 14:21:24 |
Scientific publications | Documents, reports | 2019-07-24 14:21:24 |
Qualification of donated blood | Demonstrators, pilots, prototypes | 2019-07-24 14:21:24 |
Registration number of clinical trail acquired. | Documents, reports | 2019-07-24 14:21:25 |
Study protocol finalised, approved and implemented at study site. | Documents, reports | 2019-07-24 14:21:24 |
Comprehensive community mobilization strategy initiated | Demonstrators, pilots, prototypes | 2019-07-24 14:21:23 |
Comprehensive scientific, clinical, strategic and organisational management | Documents, reports | 2019-07-24 14:21:24 |
Monitoring of virological response to treatment | Demonstrators, pilots, prototypes | 2019-07-24 14:21:24 |
Follow-up and management of press and media evaluated | Documents, reports | 2019-07-24 14:21:24 |
Contribution to international and national scientific platforms | Demonstrators, pilots, prototypes | 2019-07-24 14:21:24 |
Analysis of survival rate of patients with standardized supportive care (only). | Demonstrators, pilots, prototypes | 2019-07-24 14:21:23 |
Independent, all-inclusive Data safety management through either an Ebola centralised WHO umbrella group or ad hoc DSMB | Documents, reports | 2019-07-24 14:21:24 |
Ethical approval from overseeing Ethical Committees and Review Boards | Documents, reports | 2019-07-24 14:21:25 |
Results of trial posted on Study Registry including CWB, CP, SC | Documents, reports | 2019-07-24 14:21:23 |
Thorough ethical oversight | Documents, reports | 2019-07-24 14:21:24 |
Optimal standardized supportive care for EVD patients established. | Demonstrators, pilots, prototypes | 2019-07-24 14:21:25 |
Contribution to national (study site) and international EVD health platforms evaluated | Documents, reports | 2019-07-24 14:21:24 |
Analysis of survival rate of CP on cohort of 100 patients | Demonstrators, pilots, prototypes | 2019-07-24 14:21:23 |
Reporting and/or analysis of contingency strategies and/or treatments resulting from unidentified, unforeseen or unavoidable issues which present during the trial period. | Documents, reports | 2019-07-24 14:21:23 |
Take a look to the deliverables list in detail: detailed list of Ebola_Tx deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2016 |
A. Delamou, N. Y. Haba, A. Mari-Saez, P. Gallian, M. Ronse, J. Jacobs, B. S. Camara, K. J.-J. O. Kadio, A. Guemou, J. P. Kolie, M. D. Crop, P. Chavarin, C. Jacquot, C. Lazaygues, A. D. Weggheleire, L. Lynen, J. van Griensven Organizing the Donation of Convalescent Plasma for a Therapeutic Clinical Trial on Ebola Virus Disease: The Experience in Guinea published pages: 647-653, ISSN: 0002-9637, DOI: 10.4269/ajtmh.15-0890 |
American Journal of Tropical Medicine and Hygiene 95/3 | 2019-07-24 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBOLA_TX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EBOLA_TX" are provided by the European Opendata Portal: CORDIS opendata.